Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Non-Current Debt (2025)

CG Oncology filings provide 1 years of Non-Current Debt readings, the most recent being $3.0 million for Q4 2025.

  • On a quarterly basis, Non-Current Debt changed N/A to $3.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.0 million, a N/A change, with the full-year FY2025 number at $3.0 million, changed N/A from a year prior.
  • Non-Current Debt hit $3.0 million in Q4 2025 for CG Oncology, roughly flat from $3.0 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $3.0 million in Q3 2025 to a low of $3.0 million in Q3 2025.